HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen

AIDS ◽  
2007 ◽  
Vol 21 (17) ◽  
pp. 2341-2343 ◽  
Author(s):  
Anne-Geneviève Marcelin ◽  
Bernard Jarrousse ◽  
Anne Derache ◽  
Madina Ba ◽  
Marie-léa Dakouo ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
First Line ◽  
Hiv Drug Resistance ◽  
Dose Combination

Are fixed-dose combination antihypertensives suitable as first-line therapy?

2012 ◽  
Vol 28 (10) ◽  
pp. 1685-1697 ◽  
Author(s):  
Sverre E. Kjeldsen ◽  
Franz H. Messerli ◽  
Chern-En Chiang ◽  
Peter A. Meredith ◽  
Lisheng Liu
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Dose Combination

Postmarketing In Vitro/In Vivo Assessment of Fixed Dose Combination Products of First Line Antiretrovirals

2010 ◽  
Vol 99 (6) ◽  
pp. 2655-2663 ◽  
Author(s):  
A. Joshi ◽  
F. Esseku ◽  
L. Silva ◽  
C. Igwilo ◽  
D. Oqua ◽  
...  
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
First Line ◽  
Dose Combination ◽  
In Vivo Assessment

Duovent – is logic enough?

1985 ◽  
Vol 23 (1) ◽  
pp. 3-4
Keyword(s):  
Chronic Bronchitis ◽  
Fixed Dose Combination ◽  
British National Formulary ◽  
Fixed Dose ◽  
Line Treatment ◽  
National Formulary ◽  
First Line ◽  
Airways Obstruction ◽  
Dose Combination ◽  
First Line Treatment

Duovent (WB Pharmaceuticals) is a fixed-dose combination aerosol containing fenoterol (100 μg per puff) - a β2-adrenoceptor stimulant, and ipratropium (40 μg per puff) - an atropine-like agent. It is marketed for the treatment of bronchoconstriction in patients with asthma, chronic bronchitis or emphysema. The manufacturer claims that it is a ‘logical combination’ offering ‘first line treatment’, but the British National Formulary1 states that compound bronchodilators (including Duovent) ‘have no place in the management of patients with airways obstruction’.

scholarly journals Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir

2015 ◽  
Vol 2015 ◽  
pp. 1-2 ◽  
Author(s):  
Rashmee Patil ◽  
Mel A. Ona ◽  
Haris Papafragkakis ◽  
Jeanne Carey ◽  
Yitzchak Moshenyat ◽  
...  
Keyword(s):  
Liver Failure ◽  
Liver Transplant ◽  
Acute Liver Failure ◽  
Liver Toxicity ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hepatocellular Injury ◽  
First Line ◽  
Dose Combination

The fixed-dose combination of Efavirenz/Emtricitabine/Tenofovir is a first-line agent for the treatment of HIV; however few cases have reported hepatotoxicity associated with the drug. We report a case of Efavirenz/Emtricitabine/Tenofovir-associated hepatotoxicity presenting mainly with hepatocellular injury characterized by extremely elevated aminotransferase levels, which resolved without acute liver failure or need for liver transplant referral.

Sign in / Sign up

Export Citation Format

Share Document